Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 6/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.49 |
| ▸ | SRD5A1 | P18405 | 6/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 6/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30267074 | 1.00 | DDB1 (0.49) | DDB1CRBNSRD5A1SRD5A2GAA | |
| SCHEMBL30816905 | 0.92 | DDB1 (0.41) | DDB1CRBNSRD5A1SRD5A2LMNA | |
| SCHEMBL31697867 | 0.92 | DDB1 (0.41) | DDB1CRBNSRD5A1SRD5A2LMNA | |
| SCHEMBL25256759 | 0.90 | CRBN (0.41) | DDB1CRBNSRD5A1SRD5A2 | |
| SCHEMBL29892316 | 0.90 | CRBN (0.41) | DDB1CRBNSRD5A1SRD5A2 | |
| SCHEMBL23122938 | 0.88 | DDB1 (0.40) | DDB1CRBNSRD5A1SRD5A2 | |
| SCHEMBL31677278 | 0.88 | DDB1 (0.40) | DDB1CRBNSRD5A1SRD5A2 | |
| SCHEMBL31524286 | 0.88 | DDB1 (0.40) | DDB1CRBNSRD5A1SRD5A2 | |
| SCHEMBL21408889 | 0.87 | DDB1 (0.39) | DDB1CRBNSRD5A1SRD5A2LMNA | |
| SCHEMBL29721010 | 0.87 | DDB1 (0.39) | DDB1CRBNSRD5A1SRD5A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025228947-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF INDUCING DEGRADATION OF POLO-LIKE KINASE1 | CROSSFIRE ONCOLOGY B.V. (NL) | 2025-11-06 | — | — | WO | disclosed |
| EP-4634184-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | Crossfire Oncology Holding B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| CN-119948027-A | SOS1 protein degradation agent and application thereof | 领泰生物医药(绍兴)有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119894895-A | IRAK4 degradation agent and application thereof | 领泰生物医药(绍兴)有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20240368194-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024146502-A1 | WEE1 DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024126617-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-06-20 | — | — | WO | disclosed |
| CN-117917410-A | Pan-KRAS degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-117917416-A | KRAS G12D degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-115710274-A | IRAK4 degradation agent, preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2023-02-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | DDB1 294/4885CRBN 1994/4885SRD5A1 33/4885 |
| US-20240368194-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | DDB1 2931/4885CRBN 545/4885SRD5A1 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.